Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Tacrine

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Tacrine is currently the only treatment approved for use in Alzheimer’s disease. There is, however, considerable debate over its effectiveness due to conflicting clinical trial results. Most investigators agree, nevertheless, that a definite sub-population of patients do benefit from therapy with tacrine.

Tacrine is associated with large pharmacokinetic interindividual variation within both patient and control groups. This is thought to influence both the efficacy and incidence of symptomatic adverse effects in individual patients.

Following oral administration of tacrine the drug is rapidly and well absorbed with peak plasma concentrations (Cmax) achieved within 0.5 to 3 hours (after a single dose of 20 to 50mg). Tacrine appears to have a wide tissue distribution, which is reflected by its large volume of distribution. High concentrations of the drug were found in the kidney, liver, adrenal gland and brain tissue in animal models. It has a low bioavailability following oral intake, thought to result from extensive first-pass metabolism. Bioavailability can be increased upon rectal administration. The drug is rapidly and extensively metabolised in humans. In vitro metabolism studies have demonstrated the importance of cytochrome P450 (CYP1A2) in the biotransformation of tacrine to 1-, 2-, 4- and 7-hydroxylated metabolites. In humans, mono- and dihydroxylated tacrine and glucuronide conjugates were identified in the urine, which was the primary route of excretion. The elimination half-life of tacrine was short, 1.5 to 2.5 hours after single oral and intravenous doses and 2.9 to 3.6 hours after multiple oral doses.

At low doses (l0mg) of tacrine, the pharmacokinetic profile was nonlinear and the oral bioavailability of the drug was disproportionately low in comparison to higher doses of tacrine (20mg). This may reflect saturable hepatic uptake of the parent compound.

Both symptomatic and asymptomatic adverse effects occur frequently with tacrine therapy (32 to 80% of patients). These adverse reactions, ranging from predictable cholinergic effects to nonpredictable elevations in serum transaminase levels, can however be reversed by dosage withdrawal and/or adjustment. It has been postulated that the elevated levels of transaminase associated with tacrine therapy in vivo are dependent upon bioactivation of tacrine, mediated by hepatic CYP1A2, to form a toxic compound.

Limited data are available regarding the propensity of tacrine to interact with other drugs. In one study, concomitant administration of theophylline led to an alteration of the pharmacokinetics of theophylline, whereas an elevation of plasma tacrine concentrations results from coadministration of cimetidine. Both of these effects are thought to be due to the interaction of the agents with CYP1A2. Therefore, the potential for tacrine to be subject to interactions with other drugs that are substrates of this enzyme should be recognised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shaw FH, Bentley GA. Pharmacology of morphine, with special reference to its antagonism by 9-aminoacridine and other related compounds. Med J Aust 1949; II: 868–74

    CAS  Google Scholar 

  2. Stone V, Moon W, Shaw FH. Treatment of intractable pain with morphine and THA. BMJ 1961; 1: 471–3

    Article  PubMed  CAS  Google Scholar 

  3. Jones CR, Davis M. Replacement drug for edrophonium. Med J Aust 1975; 2: 650

    PubMed  CAS  Google Scholar 

  4. Summers WK, Kaufman KR, Altman F, et al. THA: a review of the literature and its use in the treatment of five overdose patients. Clin Toxicol 1980; 16: 269–81

    Article  PubMed  CAS  Google Scholar 

  5. McCaul K, Robinson GD. Suxamethonium extension by tetrahydroaminoacrine. Br J Anaesth 1962; 34: 536–42

    Article  PubMed  CAS  Google Scholar 

  6. Gershon S. Blocking effect of tetrahydroaminoacrin on a new psychotomimetic drug. Lancet 1960; 186: 1072–3

    CAS  Google Scholar 

  7. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241–5

    Article  PubMed  CAS  Google Scholar 

  8. Hartvig P, Askmark H, Aquilonius SM, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-l,2,3,4-tetra-hydroacridine, tacrine. Eur J Clin Pharmacol 1990; 38: 259–63

    Article  PubMed  CAS  Google Scholar 

  9. Fredj G, Dietlin F, Jasmin C, et al. Open trial of tacrine therapy in 70 HIV infected patients. Int J Clin Pharmacol Ther Toxicol 1992; 30: 313–6

    PubMed  CAS  Google Scholar 

  10. Ahlin A, Adem A, Jonthe T, et al. Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer’s patients. Int Clin Psychopharmacol 1992; 7: 29–36

    Article  PubMed  CAS  Google Scholar 

  11. Cutler NR, Sedman AJ, Prior P, et al. Steady-state pharmacokinetics of tacrine in patients with Alzheimer’s disease. Psychopharm Bull 1990; 26: 231–4

    CAS  Google Scholar 

  12. Ekman L, Lindstrom B, Roxin P. Determination of tacrine and its 1-hydroxy metabolite in plasma using column liquid chromatography with ultraviolet detection. J Chromatogr 1989; 494: 397–402

    Article  PubMed  CAS  Google Scholar 

  13. Forsyth DR, Ford JM, Truman CA, et al. Determination of tacrine hydrochloride in human serum by chloroform extraction, reversed-phase high-performance liquid chromatography and fluorometric detection. J Chromatogr 1988; 433: 352–8

    Article  PubMed  CAS  Google Scholar 

  14. Selen A, Bulogh L, Siedlik P, et al. Pharmacokinetics of tacrine in healthy subjects. Pharm Res 1988; 5: S218

    Google Scholar 

  15. Ahlin A, Nyback H, Jonthe T, et al. Tetrahydroaminoacridine in Alzheimer’s dementia clinical and biochemical results of a double-blind crossover trial. Hum Psycopharm 1991; 6: 109–18

    Article  Google Scholar 

  16. Ford JM, Truman CA, Wilcock GK, et al. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer’s disease. Clin Pharmacol Ther 1993; 53: 691–5

    Article  PubMed  CAS  Google Scholar 

  17. Nyback H, Nyman H, Ohman G, et al. Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer’s disease. In: Giacobini E, Becker R, editors. Current research in Alzheimer therapy. New York: Taylor Francis, 1988: 231–6

    Google Scholar 

  18. Forsyth DR, Wilcock GK, Truman CA, et al. Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 1989; 46: 634–41

    Article  PubMed  CAS  Google Scholar 

  19. McNally W, Roth M, Young R, et al. Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose. Pharm Res 1989; 6: 924–36

    Article  PubMed  CAS  Google Scholar 

  20. Telting-Diaz M, Lunte CE. Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharm Res 1993; 10: 44–8

    Article  PubMed  CAS  Google Scholar 

  21. Baldwin HA, de Souza RJ, Sarna GS, et al. Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses. Br J Pharmacol 1991; 103: 1946–50

    Article  PubMed  CAS  Google Scholar 

  22. Pool WF, Bjorge SM, Chang T, et al. Metabolic disposition of the cognition activator tacrine in man: identification of phenol glucuronide metabolites in urine. ISSX Proceedings Fourth North American ISSX Meeting 2; 1992 Nov: Bal Harbour, Florida. 1992: 164

  23. Truman CA, Ford JM, Roberts CJC. Comparison of the chromatographic characteristics of metabolites of tacrine hydrochloride in human serum and urine with those of in vitro metabolic products from hepatic microsomes. Biochem Pharmacol 1991; 42: 956–9

    Article  PubMed  CAS  Google Scholar 

  24. Hsu RS, Schutske GM, Dileo EM, et al. Identification of the urinary metabolites of tacrine in the rat. Drug Metab Dispos 1990; 18: 779–83

    PubMed  CAS  Google Scholar 

  25. Pool WF, Bjorge SM, Reilly MD, et al. Metabolic disposition of the cognition activator tacrine in dog: identification of dihydroxy metabolites including a dihydrodiol. ISSX Proceedings Fourth North American ISSX Meeting 2; 1992 Nov: Bal Harbour, Florida: 163

  26. Goa KL, Fitton A. Velnacrine in Alzheimers disease: an initial appraisal of its clinical potential. CNS Drugs 1994; 1: 232–40

    Article  Google Scholar 

  27. Puri SK, Hsu R, Ho I, et al. Single-dose safety, tolerance and pharmacokinetics of HP 029 in elderly men: a potent Alzheimer agent. Curr Ther Res 1988; 44: 766–80

    CAS  Google Scholar 

  28. Murphy MF, Hardiman ST, Nash RJ, et al. Evaluation of HP029 (velnacrine maleate) in Alzheimer’s disease. Ann NY Acad Sci 1991; 640: 253–62

    PubMed  CAS  Google Scholar 

  29. Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand Suppl 1993; 149: 26–8

    PubMed  CAS  Google Scholar 

  30. Madden S, Woolf TW, Pool WF, et al. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993; 46: 13–20

    Article  PubMed  CAS  Google Scholar 

  31. Woolf TF, Pool WF, Bjorge SM, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species differences. Drug Metab Dispos 1993; 21: 874–82

    PubMed  CAS  Google Scholar 

  32. Hendrickson HP, Scott DO, Lunte CE. Identification of a 9-hydroxylamine 1,2,3,4-tetrahydroacridine as a hepatic microsomal metabolite of tacrine by high-performance liquid chromatography and electrochemistry. J Chromatogr 1989; 487: 401–8

    Article  PubMed  CAS  Google Scholar 

  33. Pool WF, Bjorge SM, Chang T, et al. Effect of 3-methylcholanthrene induction on the disposition of the cognition activator tacrine in the rat. ISSX Proceedings Fourth North American ISSX Meeting 2; 1992 Nov: Bal Harbour, Florida: 165

  34. Spaldin V, Madden S, Pool WF, et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38: 15–22

    Article  PubMed  CAS  Google Scholar 

  35. Woolf TF, Pool WF, Kukan M, et al. Characterization of tacrine metabolism and bioactivation using heterologous expression systems and inhibition studies: evidence for CYP1A2 involvement. Fifth North American ISSX Meeting; 1993 Oct 17–21; Tuscon, Arizona

  36. Hooper WD, Pool WF, Woolf TF, et al. Stereoselective hydroxylation of tacrine in rats and humans. Drug Metab Dispos 1994; 22: 719–24

    PubMed  CAS  Google Scholar 

  37. Evans GH, Shand DG. Disposition of propranolol V. Drug accumulation and steady-state concentrations during chronic oral administration. Clin Pharmacol Ther 1973; 14: 487–93

    PubMed  CAS  Google Scholar 

  38. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991; 20: 736–48

    Article  PubMed  CAS  Google Scholar 

  39. Christie AB. Alzheimer’s disease: the prognosis. In: Pitt B, editor. Dementia. Edinburgh: Churchill Livingstone, 1987: 197–208

    Google Scholar 

  40. Chatellier G, Lancomblez L, on behalf of Group Francais d’Etude de la tetrahydroamino acridine. Tacrine (tetrahydro-aminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicenter trial. BMJ 1990; 300: 495–9

    Article  PubMed  CAS  Google Scholar 

  41. Gauthier S, Bouchard R, Lamontayne A, et al. Tetrahydro-aminoacrine-lecithin combination treatment in patients with intermediate stage Alzheimer’s disease: results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990; 322: 1272–6

    Article  PubMed  CAS  Google Scholar 

  42. Eagger SA, Levy R, Sahukian RJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92

    Article  PubMed  CAS  Google Scholar 

  43. Levy R. Tacrine and Alzheimer’s disease. BMJ 1990; 300: 939–40

    Article  Google Scholar 

  44. Katona CLE, O’Brien C. Tetrahydroaminoacridine and Alzheimer’s disease. Lancet 1987; 1: 444

    Article  Google Scholar 

  45. Jones RW Tacrine in Alzheimer’s disease. Lancet 1991; 337: 1475–6

    Article  Google Scholar 

  46. Wilcock GK. Tacrine and lecithin in Alzheimer’s disease [letter]. BMJ 1990; 300: 939

    Google Scholar 

  47. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled, multi-center study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327: 1253–9

    Article  PubMed  CAS  Google Scholar 

  48. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9

    Article  PubMed  CAS  Google Scholar 

  49. Knapp MJ, Knupmam DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91

    Article  PubMed  CAS  Google Scholar 

  50. Small GW. Tacrine for treating Alzheimer’s disease. JAMA 1992; 268: 2564–5

    Article  PubMed  CAS  Google Scholar 

  51. Growdon JH. Treatment for Alzheimer’s disease? N Engl J Med 1992; 327: 1306–8

    Article  PubMed  CAS  Google Scholar 

  52. Winker M. Tacrine for Alzheimer’s disease: which patient, what dose? JAMA 1994; 271: 1023–4

    Article  PubMed  CAS  Google Scholar 

  53. Eagger SA, Levy R. Serum levels of tacrine in relation to clinical response in Alzheimer’s disease. Int J Geriatr Psychiatry 1992; 7: 115–9

    Article  Google Scholar 

  54. Watkins P, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271: 992–8

    Article  PubMed  CAS  Google Scholar 

  55. Marx JC. Alzheimer’s drug trial put on hold. Science 1987; 238: 1041–2

    Article  PubMed  CAS  Google Scholar 

  56. Dogterom P, Nagelkerke JF, Mulder GJ. Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E. Biochem Pharmacol 1988; 37: 2311–3

    Article  PubMed  CAS  Google Scholar 

  57. Park BK, Madden S, Spaldin V, et al. Tacrine transaminitis: potential mechanisms. Alz Dis Assoc Disord 1994; 8 Suppl. 2: S39–S49

    Google Scholar 

  58. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in Alzheimer’s disease. Drugs Aging 1994; 4: 510–40

    Article  PubMed  CAS  Google Scholar 

  59. Robson RA, Miners JO, Matthews AP, et al. Characterisation of theophylline metabolism by human liver microsomes inhibition and immunochemical studies. Biochem Pharmacol 1987; 37: 1651–9

    Article  Google Scholar 

  60. de Vries TM, Siedlick P, Smithers JA, et al. Effect of multiple-dose tacrine administration on single-dose pharmacokinetics of digoxin, diazepam and theophylline [abstract]. Pharm Res 1993; 10: S334

    Google Scholar 

  61. de Vries TM, O’Connor-Semmes RL, Koup JR, et al. Effect of cimetidine and low-dose quinidine on tacrine pharmacokinetics in humans [abstract]. Pharm Res 1993; 10: S377

    Google Scholar 

  62. Crowley JJ, Cusack BJ, Jue SG, et al. Cigarette smoking and theophylline metabolism: effects of phenytoin. Clin Pharmacol Ther 1987; 42: 334–40

    Article  PubMed  CAS  Google Scholar 

  63. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 23–43

    Article  Google Scholar 

  64. Welty D, Pool WF, Woolf TF, et al. The effect of smoking on the pharmacokinetics and metabolism of cognex in healthy volunteers [abstract]. Pharm Res 1993; 10: 8143

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, University of Liverpool, PO Box 147, Ashton Street, Liverpool, L69 3BX, England

    Stephen Madden, Vanessa Spaldin & B. Kevin Park

Authors
  1. Stephen Madden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vanessa Spaldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Kevin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Madden, S., Spaldin, V. & Park, B.K. Clinical Pharmacokinetics of Tacrine. Clin. Pharmacokinet. 28, 449–457 (1995). https://doi.org/10.2165/00003088-199528060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199528060-00003

Keywords

Search

Navigation